HPV‐16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma
- 1 February 2009
- journal article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 140 (2) , 228-234
Abstract
Objective: To determine if patients with human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) treated with chemoradiation have improved outcomes.Study Design: A retrospective search was used to identify patients with OPSCC treated with concurrent chemoradiation. Pretreatment biopsy specimens were tested for HPV‐16 infection and p16 expression.Methods: Forty‐four patients with OPSCC treated with concurrent chemotherapy and intensity‐modulated radiation therapy were identified. Eligibility criteria included a minimum two years of follow‐up, or biopsy‐proven recurrence. In situ hybridization was applied to archival tumor specimens, with HPV‐16‐positive status defined as positive staining of tumor cell nuclei. p16 expression was assessed by immunohistochemistry.Results: Twenty‐seven tumors (61%) were positive for HPV‐16 and 29 tumors (66%) expressed p16. HPV‐16 infection was highly correlated with p16 expression (P < 10−7). Three‐year disease‐free and overall survival for all patients was 66 percent and 79 percent respectively. Patients with tumors infected with HPV‐16 had improved overall (OS) and disease‐free survival (DFS) after chemoradiation (OS: hazard ratio [HR] = 0.21, P = 0.01; DFS: HR = 0.30, P = 0.02).Conclusion: Patients with OPSCC tumors that are infected with HPV‐16 have improved survival after treatment with concurrent chemoradiation.Keywords
This publication has 22 references indexed in Scilit:
- EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal CancerJournal of Clinical Oncology, 2008
- Trends in the Use of Cigarettes and Other Tobacco Products, 2000-2007JAMA, 2008
- Cystic lymph node metastasis in patients with head and neck cancer: An HPV‐associated phenomenonHead & Neck, 2008
- Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck CancersJNCI: Journal of the National Cancer Institute, 2008
- Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Case–Control Study of Human Papillomavirus and Oropharyngeal CancerNew England Journal of Medicine, 2007
- Clinical Implications of Human Papillomavirus in Head and Neck CancersJournal of Clinical Oncology, 2006
- Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic ReviewCancer Epidemiology, Biomarkers & Prevention, 2005
- Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entitySeminars in Oncology, 2004
- Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter StudyJNCI: Journal of the National Cancer Institute, 2003